Abstracts

Distinct Gut Microbiota Composition in Gay Men

The precise effects of HIV-1 on the human microbiome are unclear. Initial cross-sectional studies provided contradictory associations between microbial richness and HIV status and suggested shifts from Bacteroides to Prevotella predominance following HIV-1 infection, which have not been found in animal models or in studies matched for HIV-1 risk groups. This was a cross-sectional study…

Enhancement of Microbiota in Macaques Leads to Beneficial Immune Function Modulation

With more than thirty million HIV-infected individuals worldwide, developing an effective vaccine to prevent new HIV infections remains a top priority in contemporary biomedical research. Given the critical role of mucosal surfaces in susceptibility to HIV, it is imperative that we induce effective mucosal responses. However, current approaches to enhance mucosal immunity have not been…

Fecal Microbial Transplantation: Safety and Engraftment During Treated HIV Infection

Despite antiretroviral therapy (ART), a substantial number of HIV-infected individuals exhibit chronic systemic inflammation. Many treated HIV-infected individuals exhibit marked alterations in the gut microbiome, and the degree of dysbiosis correlates positively with plasma markers of inflammation. Whether interventions to modulate the microbiome can affect systemic inflammation is not known. A single-arm colonoscopically delivered fecal…

Nevirapine (NVP) Concentrations in HIV-Infected Newborns Receiving Therapeutic Dosing

Very early antiretroviral treatment (ART) initiation in HIV infected newborns may limit the seeding of viral reservoirs and maintain immune responses, but few antiretroviral agents are approved for use in newborns. Prophylactic NVP dosing is well established, but the appropriate NVP dose for treatment, which requires higher NVP levels than prophylaxis, is still unknown.  While…

Pharmacokinetics, Safety, and Efficacy of Maraviroc in Pediatric Patients With R5 HIV

Maraviroc (MVC) is a CCR5 antagonist approved to treat adults infected with CCR5-tropic (R5) HIV-1. Study A4001031 was conducted to evaluate the pharmacokinetics (PK), safety and efficacy of MVC in treatment-experienced (TE) pediatric patients. This is an open-label, two-stage (stage 1: dose-finding; stage 2: safety/efficacy), age-stratified, non-comparative, multicenter study to evaluate the PK, safety and…

Safety of Tenofovir on Bone Mineral Density in HIV-Infected Youths: A 10-Year Study

HIV-infected adults receiving highly active antiretroviral therapy (HAART) containing  tenofovir DF (TDF) have decreased bone mineral density (BMD) measurements. Data in children are conflicting. The aim of this study was to assess the long-term safety of a TDF-containing HAART on BMD in a cohort of  pediatric patients. This was a single-site, longitudinal, controlled, observational study.…